ESTRELLA IMMUNOPHARMA, INC. Principal Transactions Revenue, Net
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Principal Transactions Revenue, Net of $84.09 thousand for the 9-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PrincipalTransactionsRevenue · last filed 2024-05-15
- 2024-03-31: Principal Transactions Revenue, Net 9 month $84.09K.
| Period end | Principal Transactions Revenue, Net 9 month |
|---|---|
| 2024-03-31 | $84.09K 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |